Shire acquires German biotech

Source: Healthcare Digital

Date :04/07/2008 09:31:24

Shire Ltd has bought Jerini AG for €328million, widening its footprint in human genetic therapies.

The acquisition will give Britain’s third biggest drugmaker access to Jerini’s lead product Firazyr.

Firazyr is a treatment for hereditary angioedema, a life-threatening condition.

Shire will pay €6.25 per share in cash for each Jerini share, a 71 percent premium to the company’s closing price on July 2.

It will also invest €21million in newly issued Jerini shares to fund the launch of Firazyr in Europe.